Status:
TERMINATED
Companion Pharmacogenetic Study to UMCC 9900/9901
Lead Sponsor:
University of Michigan Rogel Cancer Center
Conditions:
Metastatic Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
The purpose is to examine the original breast tumor material to see how much of a metabolizing enzyme (CYP3A4) is present in tumor material. The researchers want to see if this is in any way associate...
Eligibility Criteria
Inclusion
- Patients who participated on UMCC 9900/9901
- Living patients must give written informed consent
Exclusion
- No tumor block tissue available
Key Trial Info
Start Date :
Trial Type :
OBSERVATIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00146029
Last Update
March 26 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Michigan Cancer Center
Ann Arbor, Michigan, United States, 48109